Table 2 Comparison of the characteristics of the patients who survived versus those who did not (both tocilizumab and control groups)
Variable | Survived (n = 116) | Died (n = 153) | P value |
|---|---|---|---|
Age | 52 (44–60) | 55 (47–62) | 0.029 |
Male sex | 71 (61.2) | 105 (68.6) | 0.205 |
Hypertension | 37 (31.9) | 56 (36.6) | 0.422 |
Diabetes | 55 (47.4) | 82 (53.6) | 0.315 |
Obesity | 3 (2.6) | 11 (7.2) | 0.092 |
Other comorbidities | 8 (6.9) | 10 (6.5) | 0.907 |
Number of comorbidities | 1 (0–1) | 1 (0–2) | 0.074 |
Category | Â | Â | 0.10 |
 E | 105 (90.5) | 128 (83.7) |  |
 F | 11 (9.5) | 25 (16.3) |  |
Oxygen saturation | 91 (86–93) | 88 (83–92) | 0.002 |
CRP | 97.5 (63.5–159) | 90 (56–136) | 0.264 |
Respiratory rate | 30 (30–36) | 36 (30–40) | 0.001 |
Serum Creatinine | 1 (1–1.2) | 1.3 (1–2) | 0.001 |
SGOT | 49 (37–75) | 57 (42–72) | 0.169 |
SGPT | 40 (30–58) | 44 (28–68) | 0.977 |
LDH | 666 (275–990) | 978 (369–2000) | 1.000 |
Ferritin | 437 (293–947) | 690 (369–1257) | 0.364 |
D-dimer | 1000 (1000–1927) | 1411 (1000–5000) | 0.079 |
IL-6 | 455 (75–984) | Not available |  |
WBC counts (× 109/L) | 8.9 (5.85–13.6) | 8.55 (6.1–12.15) | 0.799 |
Platelet count (×109/L) | 200 (200–300) | 200 (200–300) | 0.314 |
CT CORAD | 6 (6–6) | 6 (6–6) | 1.000 |
CT severity score | 21 (17–24) | 24 (21–25) | 0.343 |
Thrombosis on CT | 2 of 8 | 1 of 2 | 0.490 |
Tocilizumab | 72 ((62.1) | 79 (51.6) | 0.088 |
Day of tocilizumab | 3 (2–6) | 3 (2–5) | 0.865 |
Non-invasive ventilation | 22 (19) | 34 (22.2) | 0.515 |
Invasive ventilation | 1 (0.9) | 29 (19) | 0.001 |